Acuta Capital Partners, LLC Jounce Therapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $2.28 Million - $6.24 Million	-813,500 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.01 - $8.54 $4.12 Million - $5.86 Million	686,000 Added 538.04%	813,500 $5.52 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $906,525 - $1.23 Million	127,500 New	127,500 $1.07 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.